USA flag logo/image

An Official Website of the United States Government

Kinome Drug Bioassay Platform

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
75558
Program Year/Program:
2006 / SBIR
Agency Tracking Number:
CA114995
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
REACTION BIOLOGY CORPORATION
ONE GREAT VALLEY PARKWAY MALVERN, PA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2006
Title: Kinome Drug Bioassay Platform
Agency: HHS
Contract: 2R44CA114995-02
Award Amount: $947,589.00
 

Abstract:

DESCRIPTION (provided by applicant): Reaction Biology Corporation (RBC) has developed an extremely low cost nanoliter reaction microarray to serve various drug discovery needs for high throughput screening (HTS) and compound selectivity profiling. These microarrays can hold more than 6000 individual reactions. Each reaction is 1000 to 10,000-fold smaller than those used in typical well plate formats. Kinases play a pivotal role in signal transduction and regulation of processes in cancer, inflammation, diabetes etc. However, finding selective kinase inhibitors remains a challenge. In Phase I, RBC optimized over 10 tyrosine kinase assays and 5 serine/threonine kinase assays using microarray HTS. The microarrays have been validated for kinase HTS by screening against the LOPAC library. Additionally, several phosphatase assay methodologies developed during Phase I are ready for large scale HTS campaigns. In Phase II, we propose to expand this technology to add an additional 30 kinases (Aim 1). IC50 profiling against these targets will be evaluated in both well plate and microarray format with known compounds from the LOPAC library and commercial vendors. In Aim 2, RBC will develop a universal radioisotope 33P-based kinase assay to achieve 100,000 reactions per 10 ug of purified kinase. In Aim 3, HTS campaigns using a 79,000 compound library of diverse structures against the RBC panel of kinases and phosphatases will establish a database to drive structure-activity relationship (SAR) models. Through Phase II funding, RBC will validate this kinase/phosphatase HTS platform to serve customers seeking to rapidly profile large libraries or lead series against numerous kinases chosen from the RBC assay set. Rapid HTS implementation for proprietary customer kinases using small amounts of purified protein is also a significant opportunity.

Principal Investigator:

Haiching Ma
6107220247
HAICHING@REACTIONBIOLOGY.COM

Business Contact:

Matt Oristano
6107220247
MATT@REACTIONBIOLOGY.COM
Small Business Information at Submission:

REACTION BIOLOGY CORPORATION
REACTION BIOLOGY CORPORATION ONE GREAT VALLEY PARKWAY MALVERN, PA 19355

EIN/Tax ID: 251889524
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No